argenx to Present at Upcoming Investor Conferences
May 31, 2023
Additional information regarding these events will be available on the Investors section of the argenx website at argenx.com/investors.
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, the EU and the UK. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.
For further information, please contact:
Registration Counters Open
ITEXPO, MSP Expo, Future of Work, Generative AI and Enterprise Metaverse Expo Conference Sessions